Vitamin D exhibits immunomodulatory and antiproliferative effects through vitamin D receptor (VDR) in chronic infections and cancers. We genotyped the BsmI (rs1544410), ApaI (rs7975232) and TaqI (rs731236) polymorphisms of VDR gene in 250 Taiwanese chronic hepatitis B virus (HBV) carriers who were categorized into six phenotypes. After adjustment for age and sex, the frequencies of the VDR B/b, B/a, B/T, B/a/T in patients with hepatitis flare(s) were lower than those without (7 vs 20%, P ¼ 0.009; 1 vs 9%, P ¼ 0.004; 3 vs 10%, P ¼ 0.007; 1 vs 9%, P ¼ 0.005, respectively); in contrast, T/t, A/T, A/t, b/A/t were higher in flare(s) (8 vs 3%, P ¼ 0.003; 49 vs 34%, P ¼ 0.027; 2 vs 1%, P ¼ 0.004; 0.5 vs 0%, P ¼ 0.001, respectively). 
Although effective vaccines have been available for decades, hepatitis B virus (HBV) infection remains a global health problem. It is estimated that more than 350 million persons are chronic carriers of HBV worldwide, and 75% of them are Asians. 1, 2 Even in the United States where HBV infection is endemically low, approximately 5400 people were acutely infected in 2005, 3 and 1.2 million individuals have chronic HBV infection. 4, 5 In the last few decades, the influx of immigrants from HBVendemic areas has led to increased rates of HBVassociated liver diseases and hepatocellular carcinoma (HCC) in the United States. 6 HBV infection causes a wide spectrum of clinical manifestations, ranging from acute or fulminant hepatitis to various forms of chronic liver disease, including inactive carrier state, chronic hepatitis, cirrhosis and even HCC. 2, 7 It is estimated that 5000 people in the United States die from complications of HBV including cirrhosis and HCC per annum. 8 Liver injury associated with HBV infection is predominantly mediated through immune-mediated mechanisms. 2, 9 The majority of Asian HBV carriers acquire the virus in early life, either in the perinatal period or in early childhood. 10 On the basis of the interactions between virus and host, the natural history of perinatally acquired HBV infection is usually divided into four dynamic phases: immune tolerance phase, immune clearance phase, integration or low replication phase and reactivation phase. 7 During the immune clearance phase, repeated hepatitis flares may accelerate the progression of chronic hepatitis to end-stage liver disease with poor prognosis. 11, 12 Previous studies have shown that human leukocyte antigen polymorphisms may be associated with the hepatitis activity of chronic HBV carriers. [13] [14] [15] However, the determination of whether other host immunogenetic factors also influence the severity of hepatitis flares and clinical outcomes of HBV carriers deserves additional studies.
Vitamin D is involved in the metabolism of skeleton as a systemic hormone but also has important roles in the regulation of host immune responses and development of cancer. 16 For example, vitamin D inhibits lymphocyte proliferation, stimulates monocyte differentiation and exhibits antiproliferation activities in several types of cancer cells. 17 The active form of vitamin D, 1,25-dihydroxyvitamin D, exerts immunomodulatory effects by the vitamin D receptor (VDR), 16 and high concentration of VDR is detected in the macrophages and T lymphocytes, especially CD8-positive lymphocytes. 18 The VDR locus is located at chromosome 12q13.1 with a size of more than 100 kb. Three adjacent restriction polymorphic sites in the VDR gene, the BsmI (rs1544410, A-G base change, designate as genotype B/B, B/b, b/b), ApaI (rs7975232, G-T base change, designate as genotype A/A, A/a, a/a) and TaqI (rs731236, T-C base change, designate as genotype T/T, T/t, t/t), have been reported and extensively studied in several diseases. 17 Although VDR gene variant of genotype t/t was reported to be associated with HBV clearance and active form of vitamin D was shown to inhibit HCC cell proliferation in vitro and in vivo, 19, 20 the association of VDR gene polymorphisms with distinct clinical phenotypes of chronic HBV carriers remain largely unclear. Taking advantage of rampant HBV infection in Taiwan, the aim of this study is to investigate the association of VDR gene polymorphisms with distinct clinical phenotypes of Taiwanese chronic HBV carriers as well as the risk of HCC development.
Between 1990 and 1995, a prospective cohort of 250 chronic HBV carriers (178 men and 72 women; ages, 16-70 years) was followed regularly at the gastroenterological clinic of the National Taiwan University Hospital. These carriers were followed until October 2003 when eligible patients started to receive antiviral treatments reimbursed by the National Health Insurance system. Chronic HBV carrier was defined as a carrier of hepatitis B surface antigen for at least 6 months before enrollment. Carriers who were treated with nucleot(s)ide analogs, immunomodulators or corticosteroids, with known hepatitis C, D virus or human immunodeficiency virus infections, with alcohol abuse (450 g day À1 ), intravenous drug use or hepatotoxin exposure, with positive autoimmune antibodies or known metabolic liver disease and with status of post-transplantation were excluded. The detailed description of the carriers and samples assessed in the study is presented in Table 1 .
Carriers with positive HBeAg (groups A, B and C) were significantly younger than those with negative HBeAg (groups D and E) (41.9±11.3 vs 51.7±12.6 years, Po0.001). Carriers of HBV with hepatitis flare(s) (groups B, C and D) were significantly younger than those without hepatitis flare (groups A and E) (41.5 ± 9.8 vs 51.0±13.5 years, Po0.001). Carriers of HBV without HCC (groups A, B, C, D and E) were significantly younger than those with HCC (group F) (46.2±12.9 vs 62.7 ± 17.9 years, Po0.001). There was no significant difference in terms of gender ratio, HBV DNA level and distribution of HBV genotype among the six groups.
The distribution of VDR genotype and haplotype frequencies among carriers of HBV without hepatitis flare (groups A and E) and those with hepatitis flare(s) (groups B, C and D) is shown in Table 2 . After adjustment for age and sex, the genotype frequency at BsmI site and TaqI site were significantly different between the two groups (P ¼ 0.011 and 0.012, respectively). The frequency of VDR BsmI B/b in carriers with hepatitis flare(s) was significantly lower than those without (7.2 vs 19.8%, P ¼ 0.009). The frequency of VDR TaqI T/t in carriers with hepatitis flare(s) was significantly higher than those without (7.5 vs 2.5%, P ¼ 0.0029). The frequencies of BsmI-ApaI, BsmI-TaqI, ApaI-TaqI and BsmI-ApaI-TaqI haplotypes were significantly different between the two groups (P ¼ 0.010, 0.004, 0.013 and 0.009, respectively). The frequencies of haplotype A/T, A/t and b/A/t in carriers with hepatitis flares were significantly higher than those without (48 vs 34%, P ¼ 0.027; 2 vs 1%, P ¼ 0.004; and 0.5 vs 0%, P ¼ 0.001, respectively). In contrast, the frequencies of haplotype B/a, B/T and B/a/T in carriers with hepatitis flare were significantly lower than those without (1 vs 9%, P ¼ 0.004; 3 vs 10%, P ¼ 0.007; and 1 vs 9%, P ¼ 0.005, respectively). Linkage disequilibrium was not detected among the three VDR genotypes as shown by the low D 0 values among them in Figure 1 .
The distribution of VDR genotype and haplotype frequencies among carriers of HBV with positive HBeAg (groups A, B and C) and those with negative HBeAg (groups D and E) is shown in Table 3 . After adjustment for age and sex, the genotype frequencies at BsmI and TaqI sites were significantly different between the two groups (P ¼ 0.004 and 0.002, respectively). The frequency of VDR BsmI B/b and B/B in carriers with positive HBeAg was significantly higher than those with negative HBeAg (19 vs 9%, P ¼ 0.015 and 2 vs 1%, Po0.001, respectively). The frequency of VDR TaqI T/t in carriers with positive HBeAg was significantly higher than those with negative HBeAg (7 vs 2%, P ¼ 0.002). The frequencies of VDR BsmI-ApaI, BsmI-TaqI, ApaI-TaqI and BsmI-ApaI-TaqI haplotypes were significantly different between the two groups (P ¼ 0.004, 0.002, 0.021 and 0.004, respectively). The frequencies of haplotypes b/A, B/a, B/A, B/T, B/t, A/t, b/A/T, B/a/T, B/A/T, B/A/t and b/A/t in carriers with positive HBeAg were significantly higher than those with negative HBeAg (45 vs 34%, P ¼ 0.039; 7 vs 4%, P ¼ 0.006; 4 vs 1%, Po0.001; 9 vs 5%, P ¼ 0.009; 1.8 vs 0.5%, Po0.001; 2.2 vs 0.5%, Po0.001; 44 vs 34%, P ¼ 0.043; 7 vs 4%, P ¼ 0.004; 2 vs 1%, P ¼ 0.007; 1.8 vs 0.5%, Po0.001; and 0.4 vs 0%, Po0.001, respectively).
No significant difference was found in the frequency of VDR BsmI, ApaI and TaqI genotype and haplotype between carriers with and without HCC.
To the best of our knowledge, this is the first study to investigate the association of VDR gene polymorphisms with distinct clinical phenotypes of a prospective cohort of HBV carriers and with the development of HCC. As age and sex are two important determinants of clinical phenotypes and outcomes of chronic HBV infection, [27] [28] [29] [30] all of the analyses in this study were adjusted for age and sex to evaluate the independent risk of specific VDR genotype and haplotype. The results of this study thus convincingly showed the association of VDR genotype and haplotype polymorphisms with distinct clinical phenotypes of Taiwanese HBV carriers but not with HCC development.
In this study, the activity of chronic HBV infection was determined on the basis of repeated measurements of serum alanine aminotransferase (ALT) levels. Although liver biopsy is recognized as the gold standard to evaluate hepatitis activity and fibrosis stage in patients with liver disease, its value in a large immunogenetic cohort study remains controversial because of the high cost and potential risk. In addition, a single liver biopsy at a given time point is not representative and the possibility of sampling error cannot be excluded. Therefore, monitoring the dynamic status of hepatitis activity by using repeated serum ALT measurements seems to be reasonable and practical. Moreover, Shiffman et al. 31 already indicated that chronic hepatitis patients with elevated serum ALT levels have more advanced liver histology than those with normal ALT levels. Thus, serial serum ALT levels may serve as a satisfactory surrogate marker of monitoring hepatitis activity in a large cohort of chronic HBV carriers.
At the time of this writing, only two studies on the association of VDR ApaI and TaqI polymorphism with HBV have been reported in the English literature.
19,32 An early study showed that VDR t/t genotype was associated with protection from chronic HBV infection. 19 This study confirmed that there was no t/t genotype in the chronic carriers of HBV. Another later study showed no association of VDR gene ApaI and TaqI polymorphisms with the susceptibility to HBV infection. 32 However, the researchers found that ApaI genotype a/a were associated with more severe liver disease and higher viral load. 32 As genotype a/a was the 'most common' genotype at ApaI site, it was used as the reference category in this study. The overall genotype frequency Abbreviations: ALT, alanine aminotransferase; CI, confidence interval; HBV, Hepatitis B virus; HCC, hepatocellular carcinoma; OR, odds ratio; ULN, upper limit of normal. Data are reported as means ± s.d. or counts (%). HBV carriers were categorized into six distinct groups as previously described. 21 Group A: positive for HBeAg at enrollment, no hepatitis flare or HBeAg seroconversion during follow-up; Group B: positive for HBeAg at enrollment, had episode(s) of hepatitis flare before HBeAg seroconversion; Group C: positive for HBeAg at enrollment, had episodes of hepatitis flare without HBeAg seroconversion at the end of follow-up; Group D: negative for HBeAg at enrollment, had episode(s) of hepatitis flare during follow-up; Group E: negative for HBeAg at enrollment, no hepatitis flare during follow-up; Group F: occurrence of HCC at enrollment or during follow-up, HCC was diagnosed by noninvasive diagnostic criteria or liver biopsy when the criteria were not fulfilled. 22 Acute hepatitis flare was defined as an abrupt increase of serum ALT (40 IU l
À1
) to a level greater than five times the ULN (200 IU l À1 ). 23 Serum ALT was assayed every 3 months for those with ALT elevations and every 6 months for those with normal levels. Serum samples were stored at À20 1C until use. Serum a-fetoprotein was checked and ultrasound examination was carried out to all of them every 6 months for the surveillance of HCC. Human experimentation guidelines of the authors' institutions were followed, and inform consent was obtained from each patient. Serum HBsAg and HBeAg were tested by Ausria-II and IMx HBe 2.0 (Abbott Laboratories, North Chicago, IL, USA), respectively. Serum anti-HCV and anti-HDV were assayed by Murex anti-HCV and Murex anti-delta (Murex Biotech, Kyalami, South Africa and Murex Biotech, Dartford, UK), respectively. Quantification of serum HBV DNA and identification of HBV genotype were carried out by real-time-PCR and melting curve analysis, respectively. Table 2 ). Although age-and sex-matched controls were enrolled in the previous study, comparisons of the severity of liver disease and HBV viral loads among the patients were not adjusted for age and sex, which The 'most common' type of each genotype or haplotype was used as the reference category so that the OR can be used to compare between each genotype or haplotype. Empirical P-values were calculated by 10 000 permutations and round to the third digit of decimals. Permutation analysis was used to handle multiple testing issues. Haplotypes were inferred using SAS. All of the tests were two-tailed and a P-value of less than 0.05 was considered statistically significant. Genomic DNA was extracted from peripheral blood leukocytes. 24 Genotypes for three restriction polymorphic sites (BsmI site [rs1544410] and ApaI site [rs7975232] are located within intron 7 and intron 8 of the VDR gene, respectively, whereas TaqI [rs731236] is located within the 9th exon.) were identified by the PCR followed by restriction fragment length polymorphism method modified from a previous report. 24 In brief, the forward primer for the BsmI polymorphism in exon 7 was 5 0 -CAACCAAGACTACAAGTACCGCGTCAGTGA-3 0 and the reverse primer for the BsmI polymorphism in intron 7 was 5 0 -AACCAGCGG GAAGAGGTCAAGGG-3 0 . The forward primer for the ApaI and TaqI polymorphisms, located in intron 8, was 5 0 -CAGAGCATGGACAGG GAGC-3 0 and the reverse primer located in exon 9 was 5 0 -AGGAGAGGCAGCGGTACTG-3 0 . The PCR conditions for the BsmI polymorphism were 94 1C for 5 min and 35 cycles using the following temperature profile: 94 1C for 30 s, 66 1C for 30 s and 72 1C for 30 s. Cycling was concluded with a final extension at 72 1C for 5 min. The PCR conditions for the ApaI and TaqI polymorphisms were the same as described above, except with an annealing temperature of 68 1C. The PCR product for BsmI polymorphism was 800 bp long, and was cut to two restriction fragments of 600 and 200 bps in the presence of BsmI site. The PCR products for the ApaI and TaqI polymorphisms were 480 bps long. In the presence of the respective restriction sites, the lengths of the restriction fragments were 250 and 230 bps for ApaI, and 280 and 200 bps for TaqI. Digested fragments were separated on 2% agarose gels and were visualized by ethidium bromide staining. 
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Y-W Huang et al might undermine their major findings. In addition, the study populations were different, the previous study included patients with ALT of 41.5 times upper limit of normal, and we recruited carriers with normal ALT and ALT of 45 times upper limit of normal. Furthermore, the result of previous study was only based on a single liver biopsy and once quantifiable HBV DNA without paired biopsies or serial HBV DNA measurements to monitor the dynamic changes of liver inflammation as well as viremia. In addition, two other studies in Chinese literature with English abstracts, both by same group of researchers, revealed insignificant association between VDR gene TaqI genotype and HBV carriers; 33, 34 these inconsistent findings may be because of the poorly defined clinical phenotypes and retrospective study design with no regular monitoring of the subjects under study.
Vitamin D receptor genotype B/b, haplotype B/a, B/T and B/a/T were associated with protection against hepatitis flare(s) in this study. These findings imply that HBV carrier with this genotype or haplotype may have less severe liver disease and thus less treatment is required. In addition, genotype T/t, haplotype A/T, A/t and b/A/t were associated with hepatitis flare(s), which predict adverse clinical outcomes in HBV carriers. 11, 12 These findings suggest that carriers with these haplotypes should be closely followed up to determine the time point for aggressive treatment in order to subsequently improve long-term outcomes. The current standard level of care is to monitor HBV carriers by serum ALT level every 3-6 months; 35 patients with these genotypes or haplotypes, as well as with hepatitis flare(s)-associated genotypes or haplotypes, should then be monitored every 1-2 months.
This study also revealed the association of VDR gene polymorphisms with HBeAg positivity. HBeAg is a serological marker of active HBV replication, and seroconversion of HBeAg usually confers a favorable outcome in Asian HBV carriers. 27 This finding implies the association of VDR gene with the replication activity of HBV, thus HBV carrier with the genotype or haplotype associated with HBeAg positivity, that is, genotype B/b, B/B, T/t or haplotype b/A, B/a, B/A, B/T, B/t, A/t, b/A/T, B/a/T, B/A/T, B/A/t and b/A/t, should also be closely followed up to decide the best time for treatment.
This study links the VDR gene polymorphisms to the clinical courses of chronic HBV carriers in Taiwan. These results lent support to the hypothesis that the candidate gene is at least in part involved in disease progression and may be a key to advance the management of chronic hepatitis B. Further functional studies regarding these genetic polymorphisms are needed to clarify the molecular mechanisms. As shown in the association of VDR gene polymorphisms with other diseases, 36 the effect of VDR gene polymorphisms on the course of HBV infection may be different in different ethnicities. Our data did not show linkage disequilibrium among these VDR genotypes, implying that the significance in haplotype association was referred to allelic interaction rather than haplotype due to linkage disequilibrium.
Vitamin Low follow-up rates and limited number of cases were the major limitations in our study. We overcame the difficulty of small sample size by using permutation test. 37 Permutation test is a nonparametric approach and has been used to obtain the empirical P-value through simulation by resampling study subjects. This test has been used to control type 1 error for multiple testing because of the limited sample size. If the disease status is exchangeable under the null hypothesis, then the resulting tests will yield exact significance levels when the original distribution is unknown or size is relatively small.
No association of VDR BsmI, ApaI and TaqI polymorphism with the risk of HCC was found in this study, suggesting a minimal role of VDR gene polymorphisms in hepatocarcinogenesis. However, the antiproliferative effects of active form of vitamin D against HCC cell had been reported to correlate with intracellular VDR level. 38 A vitamin D analog, Seocalcitol, had been used to treat patients with inoperable HCC. 39 Nevertheless, no further controlled studies have been carried out. Further studies are needed to clarify the role of vitamin D and VDR in the development and control of HCC. In most groupings, men outnumber women. However, as VDR polymorphisms are autosomal polymorphisms, haplotypes constituted by BsmI-ApaI, BsmI-TaqI, ApaITaqI and BsmI-ApaI-TaqI are not significantly different across different gender either (P-value ¼ 0.094, 0.319, 0.713, 0.302, respectively, data not shown), suggesting that there is no modification of VDR haplotype frequencies by gender. However, these results cannot rule out the possibility that VDR haplotypes interact with genes from sex chromosome, sex-linked or gender-specific factors. Although statistically not significant, gender is known to be an important factor for liver disease progression in HBV carriers and it was thus included in our analyses.
The HBV carriers positive for HBeAg in this study were obviously younger than those negative for HBeAg, and patients with hepatitis flares were younger than those without. These observations were in line with previous studies on the natural history of Asian patients with chronic HBV infection. 27 In summary, these findings convincingly showed the association of VDR genotype and haplotype polymorphisms with hepatitis flares and HBeAg positivity in Taiwanese HBV carriers.
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